Global Seasonal Affective Disorder Market – Industry Trends and Forecast to 2030

Global Seasonal Affective Disorder Market, By Type (Fall & Winter SAD, Spring & Summer SAD, Others), Diagnosis (Physical Exam, Lab Tests, Psychological Evaluation, Others), Treatments (Light Therapy, Medications, Psychotherapy, Counselling, Others), End Use (Hospitals, Clinics, Research Institutes, Others) – Industry Trends and Forecast to 2030.

Seasonal Affective Disorder Market Analysis and Size

The seasonal affective disorder (SAD) market is growing due to increasing awareness, technological advancements, and the prevalence of the disease. Factors such as a supportive regulatory environment, and growing awareness about mental health and disease burden are contributing to the market expansion.

Data Bridge Market Research analyses that the seasonal affective disorder market which was USD 747.63 million in 2022, would rocket up to USD 869.10 million by 2030, and is expected to undergo a CAGR of 5.25% during the forecast period. This indicates the market value. “Lab Tests” dominates the physical exam segment of the seasonal affective disorder market owing to the rise in bipolar disorder has increased the demand for diagnosis of seasonal affective disorder, which in turn works for the overall growth of the target segment. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Seasonal Affective Disorder Market Scope and Segmentation

Market Definition

Seasonal affective disorder (SAD) refers to a type of depression that occurs at a certain time of the year depending on the change of seasons, it generally occurs in winter and is normally found in women or people that are aged between 15 and 55 or people who live far from the equator where winter daylight hours are very brief.

Global Seasonal Affective Disorder Market Dynamics

Drivers

• Rising prevalence of seasonal affective disorder

The prevalence of seasonal affective disorder is increasing worldwide, mainly due to changing lifestyles, increasing urbanization, and decreasing natural sunlight. As more people are diagnosed with seasonal affective disorder, the demand for treatments and therapies to alleviate its symptoms is increasing, driving the market.

• Increasing awareness about the seasonal affective disorder

The growing awareness of seasonal affective disorder and its symptoms among the general public and healthcare professionals is increasing the demand for diagnostic and treatment options. This increased awareness leads to earlier detection and intervention, leading to a wider market for seasonal affective disorder products and services.

• Research and development proficiencies

Rising expenditure for research and development proficiencies especially in the developed and developing economies pertaining to the treatment of seasonal affective disorder will further create lucrative market growth opportunities. Research and development proficiencies being conducted to develop the new treatment for the disorder is also bolstering the market growth rate.

• Growing investment for healthcare facilities

Surging focus on improving the condition of healthcare facilities and improving the overall healthcare infrastructure is another important factor fostering the growth of the market. The rising number of partnerships and strategic collaborations between the public and private players pertaining to funding and application of new and improved technology is further creating lucrative market opportunities.  

Opportunities

• Technological advancement in the market

Advances in technology have led to the development of innovative products and treatments for seasonal affective disorder. For Instance, advanced phototherapy devices with improved functions and features are now available to provide more effective and convenient treatment options for seasonal affective disorder patients.

• Increasing adoption of online platforms and telehealth services

The widespread adoption of online platforms and telehealth provides a significant market opportunity. Offering virtual consultations, therapy sessions, and online sales of seasonal affective disorder products can improve accessibility for people who may face geographic barriers or wish to use remote services.

Restraints

• High cost associated with the treatment of seasonal affective disorder

The costs associated with seasonal affective disorder treatment, including phototherapy equipment, medications, therapy sessions, and additional therapies, can be a major limitation. High treatment costs can limit the affordability and availability of seasonal affective disorder-related products and services, especially in areas with limited health care or lower income.

• Side effects and safety concerns with the treatment

Some seasonal affective disorder treatments, such as medications or certain light therapy devices, may have potential side effects or safety concerns. This can prevent individuals from seeking or continuing treatment, affecting market growth and the adoption of certain procedures.

Challenges

• Lack of long-term studies

Long-term studies on the efficacy and safety of seasonal affective disorder treatment are limited. Collecting data on long-term outcomes, recurrence rates, and potential side effects of various interventions is difficult. In-depth long-term studies are needed to demonstrate the continued efficacy and safety of different treatment options.

• Limited reimbursement and insurance coverage

Reimbursement terms and insurance coverage for seasonal affective disorder treatment may vary between regions and health systems. Limited reimbursement or lack of coverage for certain treatments or devices may affect market growth and patient access to appropriate treatments.

This seasonal affective disorder market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the powered surgical instruments market contact Data Bridge Market Research for an Analyst Brief, our team will help you make an informed market decision to achieve market growth.

Recent Development

• In February 2022, Granules India received approval from the US Food and Drug Administration to market Bupropion Hydrochloride extended-release tablets for the treatment of major depressive disorder and seasonal affective disorder in the United States.
• In June 2021, the US Food and Drug Administration approved Alkermes plc's new drug for the treatment of schizophrenia and bipolar disorder. Lybalvi combines the active ingredient in Eli Lilly's Zyprexa with a newer chemical called samidorfan in a drug marketed as Lybalvi.

Global Seasonal Affective Disorder Market Scope

The seasonal affective disorder market is segmented on the basis of type, physical exam, treatments, end use. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Fall & Winter SAD
• Spring & Summer SAD
• Others

Diagnosis

• Physical Exam
• Lab tests
• CBC
• Thyroid blood test
• Others
• Psychological evaluation
• Intelligence tests
• Personality tests
• Attitude tests
• Achievement tests
• Aptitude tests
• Neuropsychological tests
• Vocational tests
• Direct observation tests
• Others
• Others

Treatment

• Light Therapy
• Medications
• Antidepressants
• Reuptake inhibitors (SSRIs)
• Monoamine Oxidase inhibitors
• Others
• Others
• Psychotherapy
• Art therapy
• Attachment-based psychotherapy
• Behavioral therapy
• Body psychotherapy
• Cognitive analytical therapy (CAT)
• Existential psychotherapy
• Gestalt therapy
• Others
• Counseling
• Others

End Use

• Hospitals
• Clinics
• Research Institutes
• Others

Seasonal affective disorder market regional analysis/insights

The seasonal affective disorder market is analysed and market size insights and trends are provided by country, type, physical exam, treatments, and end use as referenced above.

The countries covered in the seasonal affective disorder market report are U.S., Canada, and Mexico in North America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Rest of Europe in Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific in the Asia-Pacific (APAC), South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of the Middle East & Africa as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is expected to dominate the seasonal affective disorder market because of the strong base of healthcare facilities, strong presence of major players in the market, increases cases of seasonal affective disorder among the population, and rising number of research activities in this region.   

Asia-Pacific is expected to witness significant growth during the forecast period of 2023 to 2030 due to the increase in government initiatives to promote awareness, rise in medical tourism, growing research activities in the region, availability of massive untapped markets, large population pool, and the growing demand for quality healthcare in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends, and porter's five forces analysis, and case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure Growth Installed Base and New Technology Penetration

The seasonal affective disorder market also provides you with a detailed market analysis for every country's growth in healthcare expenditure for capital equipment, installed base of different kinds of products for the seasonal affective disorder market, the impact of technology using lifeline curves, and changes in healthcare regulatory scenarios and their impact on the seasonal affective disorder market. The data is available for the historic period 2021-2030.

Competitive Landscape and Global Seasonal Affective Disorder Market Share Analysis

The seasonal affective disorder market competitive landscape provides details of competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width, and breadth, application dominance. The above data points provided are only related to the companies' focus related to the seasonal affective disorder market.

Some of the major players operating in the seasonal affective disorder market are:

• Pfizer Inc. (U.S.)
• Lily (U.S.)
• GlaxoSmithKline (U.K.)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Bausch Health Companies Inc. (Canada)
• Viatris Inc. (U.S.)
• Johnson & Johnson (U.S.)
• Novartis AG (Switzerland)
• Sanofi (France)
• Koninklije Philips N.V. (Netherlands)
• Beurer GmbH (Germany)
• Lucimed (Belgium)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Bayer AG (Germany)
• AbbVie Inc. (U.S.)
• Bristol-Myers Squibb Company (U.S.)
• Janssen Pharmaceuticals, Inc. (Belgium)
• Carex (U.S.)
• The SunBox Company (U.S.)
• Henry Schein, Inc. (U.S.)